Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APTIVATE: Tuspetinib (HM43239) in Relapsed or Refractory Acute Myeloid Leukemia
2023-503244-14-00Phase 2Completed
- Sponsor
- Aptose Biosciences Inc.
- Start
- Jun 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of tuspetinib in acute myeloid leukemia (AML), sponsored by Aptose Biosciences Inc. Primary endpoints: Safety and tolerability of tuspetinib, Pharmacokinetics of tuspetinib and 1 more. Started Jun 2023; status: completed.
02
Drugs
tuspetinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-503244-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503244-14-00.